SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Strides Pharma Science Ltd

BSE: 532531 NSE: STAR ISIN: INE939A01011
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Strides Pharma Science Ltd belong to?
Strides Pharma Science Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Strides Pharma Science Ltd a good quality company?
Strides Pharma Science Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Strides Pharma Science Ltd undervalued or overvalued?
Strides Pharma Science Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Strides Pharma Science Ltd a good buy now?
Strides Pharma Science Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Strides Pharma Science Ltd?
Strides Pharma Science Ltd revenue growth is 14.7% for FY-2025 , which is above its 5 year CAGR of 4.8% , indicating faster growth.
Q.2 Gross Profit margin of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.6% for FY-2025 , which is above its 5 year median of 6.4% , indicating increasing margins.
Q.3 Operating Profit Margin of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 11.75% for FY-2025 , which is above its 5 year median of 7.62% indicating increasing margins.
Q.4 Net Profit Margin of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Net Profit Margin is 2.77% for FY-2025 , is in line with with its 5 year median of 2.77%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 7.6 6.4
Operating Profit Margin 11.75 7.62
Net Profit Margin 2.77 2.77
Q.5 Return on Asset of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Return on Asset is 1.1%, which is in line with its 5 year historical median of 1.1%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Return on equity is 1.76% for FY-2025 , which is in line with its historical median of 1.76%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Return on capital employed is 4.71% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 13.5%, indicating value preservation.
Q.8 Cash conversion cycle of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Cash conversion cycle is 238 days, above its historical median of 221 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.4 0.38
ROE 1.76 1.76
ROCE 4.71 2.34
Cash Conversion Cycle 238 days 221 days
Q.9 Debt to Equity ratio of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Debt-to-Equity ratio is 0.36 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Strides Pharma Science Ltd?
Strides Pharma Science Ltd Debt to cash flow from operations is 2.74 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Strides Pharma Science Ltd?
Promoters hold 27.86% of the Strides Pharma Science Ltd, with 30.60% of their stake pledged, indicating high pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Strides Pharma Science Ltd vs industry peers?
Strides Pharma Science Ltd revenue CAGR is 4.81% , compared to the industry median CAGR of 5.51% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,139.4 138.8
Gross Profit 162.6 16.2
Operating Profit 251 16
Net Profit 59 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.4 0.79
ROE 1.76 9.17
ROCE 4.71 11.78
Cash Conversion Cycle (days) 237.92 76

Valuation & price assessment

Q.1 Stock return of Strides Pharma Science Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -1.1% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -1.1% 2.1% 45.2% 55.4%
Q.3 Valuation ratios of Strides Pharma Science Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 50.05 56.09 40.28
Price to Book 2.78 1.72 2.77
Price to Sales 4.31 3.28 2.65
EV to EBITDA 25.3 22.09 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Eris Lifesciences
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×